scholarly journals Dose tailoring of human cell line‐derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A

2019 ◽  
Vol 85 (4) ◽  
pp. 771-781 ◽  
Author(s):  
Xavier Delavenne ◽  
Yesim Dargaud ◽  
Edouard Ollier ◽  
Claude Négrier
Keyword(s):  
Factor Viii ◽  
Cell Line ◽  
Human Cell ◽  
Sampling Strategy ◽  
Human Cell Line ◽  
Recombinant Factor Viii ◽  
Limited Sampling Strategy ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Limited Sampling

scholarly journals Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq ® ) in adults with severe haemophilia A: efficacy and safety

Haemophilia ◽  
2015 ◽  
Vol 22 (2) ◽  
pp. 225-231 ◽  
Author(s):  
T. Lissitchkov ◽  
K. Hampton ◽  
M. Depka ◽  
C. Hay ◽  
S. Rangarajan ◽  
...  
Keyword(s):  
Factor Viii ◽  
Cell Line ◽  
Human Cell ◽  
Human Cell Line ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Efficacy And Safety

A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3309-3309 ◽  
Author(s):  
Sigurd Knaub ◽  
Andreas Tiede ◽  
Toshko Lissitchkov ◽  
Leonard A. Valentino ◽  
Jerry Sherman Powell ◽  
...  
Keyword(s):  
Factor Viii ◽  
Cell Line ◽  
Human Cell ◽  
Hemophilia A ◽  
Human Cell Line ◽  
Recombinant Factor Viii ◽  
Baby Hamster Kidney ◽  
Efficacy And Safety ◽  
One Stage ◽  
The One

Abstract Abstract 3309 Introduction: human-cl rhFVIII is the first recombinant factor VIII (FVIII) concentrate expressed in a human cell line (Human Embryonic Kidney (HEK) 293F cells). The manufacturing process includes two steps for virus inactivation and removal (solvent/detergent treatment and a nanofiltration). No animal- or human-derived materials are added to the culture medium or during the purification and final formulation. Objective: The primary objective of this study is to compare the pharmacokinetics (PKs) of human-cl rhFVIII, a B-domain deleted rFVIII product expressed in a human cell line, with a commercially available full-length rFVIII product (Kogenate FS), which is expressed in Baby Hamster Kidney (BHK) cells. Methods: This study is an open, multinational, prospective, multicenter clinical phase-II trial. The PK properties of human-cl rhFVIII and Kogenate FS were determined using a randomized two-period, cross-over design. After a 96 hours or more wash-out phase of any previously administered FVIII product, subjects received a single intravenous dose of 50 IU/kg body weight of one of the products. Blood samples were collected over a 48-h period and FVIII coagulant activity (FVIII:C) was measured by validated chromogenic substrate and one-stage clotting assay in a central laboratory, which also assigned drug potency with the same assays. Following completion of the PK segment of the study, subjects will be followed for at least 50 Exposure Days and at least 6 months of treatment with human-cl rhFVIII to evaluate the efficacy and safety of on-demand treatment. The planned interim analysis stipulates the comparison of the complete PK profile of human-cl rhFVIII and Kogenate FS with the bioequivalence of the AUC as the primary endpoint. The full efficacy and safety profile will be reported when the study is completed. Results: Twenty-two adolescent and adult PTPs with severe hemophilia A (FVIII:C <1%) were enrolled at 10 study centers in the United States and Europe. The key PK parameters (AUC, elimination half-life, in-vivo recovery, clearance) are comparable between human-cl rhFVIII and Kogenate FS both for the one-stage and chromogenic assays. The two products were judged to be bioequivalent as the 90% confidence interval of the ratio of the geometric mean values of the AUC fell within 80–125%. human-cl rhFVIII has been well tolerated and no safety or efficacy issues have been reported so far, in particular no inhibitors or non inhibitory antibodies were detected or reported. Conclusion: The PK data from this study indicate that human-cl rh FVIII is bioequivalent to a licensed rFVIII concentrate measured by the one stage and the chromogenic assays. In this study as well as in the other ongoing clinical studies, which examine the efficacy and safety of human-cl rhFVIII during prophylactic treatment in children and adults with severe hemophilia A, the product has been safe and well tolerated so far. Disclosures: Knaub: Octapharma AG: Employment. Valentino:Baxter Bioscience: Consultancy; GTC Biotherapeutics: Consultancy; Bayer Healthcare: Consultancy; NovoNordisk: Consultancy; Inspiration Bioscience: Consultancy; Biogen: Consultancy. Manco-Johnson:Octapharma AG: Consultancy.

The First Human Cell Line Recombinant Factor VIII (Human-cl rhFVIII) - Functional Properties and Differences From Currently Available Recombinant Factor VIII Products.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1298-1298
Author(s):  
Bruce A. Schwartz ◽  
Helena Sandberg ◽  
Irene Agerkvist ◽  
Christoph Kannicht ◽  
Margareta Ramström ◽  
...  
Keyword(s):  
Factor Viii ◽  
Cell Line ◽  
Functional Properties ◽  
Human Cell ◽  
Specific Activity ◽  
Activated Protein C ◽  
High Specific Activity ◽  
Human Cell Line ◽  
Recombinant Factor Viii ◽  
Chromogenic Assay

Abstract Abstract 1298 Poster Board I-320 All current recombinant factor VIII products produced today are derived from the expression of FVIII in hamster cell lines. This is a report of the functional properties of a newly developed recombinant factor VIII concentrate produced in a human cell line. The possible advantage of using a human cell line for expression of recombinant factor VIII is that a human pattern of post-translational modifications (PTM), such as glycosylation, are obtained. These human like PTMs, may possibly lead to improved function and a reduced immunogenic product profile compared to recombinant factor VIII products from CHO or BHK cells that have hamster-specific PTM. Data are presented on the characteristics of the Human-cl rhFVIII, a B-domain-deleted factor VIII protein produced in HEK293F cells, and how they compare with those of other factor VIII products. Human-cl rhFVIII is highly pure (>99.9% purity) with a high specific activity of 8000-11000 IU/mg protein, and a FVIII:C to FVIII:Ag ratio close to 1.0. This indicates that the entire factor VIII protein in the product is active. Human-cl rhFVIII showed no significant assay discrepancy between one-stage and chromogenic assay results. Because of the human glycosylation profile of the new Human-cl rhFVIII, there was an absence of the antigenic type of sialic acid, N-glycolylneuraminic acid as well as of antigenic Galα (1,3) Gal epitopes found in the non humane derived products. Another type of PTM of factor VIII is the sulfation of certain tyrosines that are crucial for the biological function e.g. the interaction with von Willebrand factor (vWF). Human-cl rhFVIII was found to be optimally sulfated when compared to endogenous human FVIII. In this context, it is of interest to note that Human cl-rhFVIII showed a 60% higher affinity in binding to vWF compared to other recombinant factor VIII products and the number of molecules in the product able to bind to vWF was significantly higher for Human-cl rhFVIII. Interaction with thrombin and capacity to generate thrombin were shown to be similar to those of plasma-derived factor VIII. The sensitivity to be inactivated by activated protein C was similar to all currently licensed rhFVIII products. The important properties of Human cell line derived recombinant factor VIII may be very promising for its use in future treatment of Haemophilia A. Disclosures Schwartz: Octapharma: Employment. Sandberg:Octapharma: Employment. Agerkvist:Octapharma: Employment. Kannicht:Octapharma: Employment. Ramström:Octapharma: Employment. Stenlund:Octapharma: Employment. Oswaldsson:Octapharma: Employment. Brunberg:Octapharma: Employment.

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting

2008 ◽  
Vol 99 (01) ◽  
pp. 52-58 ◽  
Author(s):  
Elena Santagostino ◽  
Albert Faradji ◽  
Alfonso Iorio ◽  
Jan van der Meer ◽  
Jørgen Ingerslev ◽  
...  
Keyword(s):  
Observational Study ◽  
Factor Viii ◽  
De Novo ◽  
Observation Time ◽  
Full Length ◽  
Recombinant Factor Viii ◽  
Phase Iii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Safety And Efficacy

SummaryThe safety of full-length sucrose-formulated recombinant factor VIII (rFVIII-FS; KOGENATE® FS) for up to 24 months of use was evaluated in a postmarketing observational study in Europe. Long-term safety and efficacy data were available for 212 patients with severe haemophilia A, including 13 previously untreated patients (PUPs) and 12 patients with 1–19 exposure days (EDs). Patients accumulated a mean (± SD) of 187 (121) EDs to rFVIII-FS and received a total of 39,627 infusions, mainly for prophylaxis and for the treatment of 4,283 spontaneous or trauma-related bleeds during an average observation time of 710 (136) days. Of these bleeding episodes, 85.4% were successfully treated with one or two infusions of rFVIII-FS. Haemostasis was also evaluated during 46 minor to major surgical pro- cedures, and the response to infusion was “excellent” or “good” in all cases. FVIII inhibitor formation was observed in six patients (two de novo; four persistent or recurrent). The de novo cases represent 8.0% (2 of 25) of patients who reported 0–19 previous EDs at study entry. Four of the five patients who reported possible drug-related adverse effects developed inhibitors. The results of this observational study demonstrate the efficacy and safety of rFVIII-FS during normal clinical use in the treatment of patients with severe haemophilia A. Furthermore, these findings are consistent with those of previous phase III clinical studies with rFVIII-FS, particularly with regard to its efficacy and low incidence of inhibitor formation.

Sign in / Sign up

Export Citation Format

Share Document